# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.25) by ...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
Morgan Stanley analyst Judah Frommer assumes ProKidney (NASDAQ:PROK) with a Equal-Weight rating and announces Price Target o...